<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38383493</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Fatigue and symptom-based clusters in post COVID-19 patients: a multicentre, prospective, observational cohort study.</ArticleTitle><Pagination><StartPage>191</StartPage><MedlinePgn>191</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">191</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-024-04979-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">In the Netherlands, the prevalence of post COVID-19 condition is estimated at 12.7% at 90-150&#xa0;days after SARS-CoV-2 infection. This study aimed to determine the occurrence of fatigue and other symptoms, to assess how many patients meet the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) criteria, to identify symptom-based clusters within the P4O2 COVID-19 cohort and to compare these clusters with clusters in a ME/CFS cohort.</AbstractText><AbstractText Label="METHODS">In this multicentre,&#xa0;prospective, observational cohort in the Netherlands, 95 post COVID-19 patients aged 40-65&#xa0;years were included. Data collection at 3-6&#xa0;months after infection included demographics, medical history, questionnaires, and a medical examination. Follow-up assessments occurred 9-12&#xa0;months later, where the same data were collected. Fatigue was determined with the Fatigue Severity Scale (FSS), a score of&#x2009;&#x2265;&#x2009;4 means moderate to high fatigue. The frequency and severity of other symptoms and the percentage of patients that meet the ME/CFS criteria were assessed using the DePaul Symptom Questionnaire-2 (DSQ-2). A self-organizing map was used to visualize the clustering of patients based on severity and frequency of 79 symptoms. In a previous study, 337 Dutch ME/CFS patients were clustered based on their symptom scores. The symptom scores of post COVID-19 patients were applied to these clusters to examine whether the same or different clusters were found.</AbstractText><AbstractText Label="RESULTS">According to the FSS, fatigue was reported by 75.9% of the patients at 3-6&#xa0;months after infection and by 57.1% of the patients 9-12&#xa0;months later. Post-exertional malaise, sleep disturbances, pain, and neurocognitive symptoms were also frequently reported, according to the DSQ-2. Over half of the patients (52.7%) met the Fukuda criteria for ME/CFS, while fewer patients met other ME/CFS definitions. Clustering revealed specific symptom patterns and showed that post COVID-19 patients occurred in 11 of the clusters that have been observed in the ME/CFS cohort, where 2 clusters had&#x2009;&gt;&#x2009;10 patients.</AbstractText><AbstractText Label="CONCLUSIONS">This study shows persistent fatigue and diverse symptomatology in post COVID-19 patients, up to 12-18&#xa0;months after SARS-CoV-2 infection. Clustering showed that post COVID-19 patients occurred in 11 of the clusters that have been observed in the ME/CFS cohort.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cornelissen</LastName><ForeName>Merel E B</ForeName><Initials>MEB</Initials><Identifier Source="ORCID">0009-0004-5707-4673</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands. m.e.b.cornelissen@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands. m.e.b.cornelissen@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. m.e.b.cornelissen@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloemsma</LastName><ForeName>Lizan D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaes</LastName><ForeName>Anouk W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Ciro, Horn, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baalbaki</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Qichen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Ciro, Horn, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nutrim Institute of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beijers</LastName><ForeName>Rosanne J H C G</ForeName><Initials>RJHCG</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nutrim Institute of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noij</LastName><ForeName>Lieke C E</ForeName><Initials>LCE</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houweling</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazdar</LastName><ForeName>Somayeh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spruit</LastName><ForeName>Martijn A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Ciro, Horn, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nutrim Institute of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maitland-van der Zee</LastName><ForeName>Anke H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>the P4O2 Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clusters</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">Persistent symptoms</Keyword><Keyword MajorTopicYN="N">Post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Post-viral condition</Keyword></KeywordList><CoiStatement>M.E.B.C., L.D.B., N.B., R.J.H.C.G.B., L.H., L.C.E.N. and A.H.M.: Public and private partners in the P4O2 consortium, as listed under &#x2018;funding&#x2019;. M.A.S. reports grants from Lung Foundation Netherlands, grants from Stichting Astma Bestrijding, grants and fees from Boehringer Ingelheim, and grants and personal fees from AstraZeneca, outside the submitted work. All payments were done to M.A.S. employer. S.B., A.W.V. and Q.D. declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>22</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38383493</ArticleId><ArticleId IdType="pmc">PMC10880228</ArticleId><ArticleId IdType="doi">10.1186/s12967-024-04979-1</ArticleId><ArticleId IdType="pii">10.1186/s12967-024-04979-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . WHO Coronavirus (COVID-19) Dashboard. Geneva: WHO; 2022.</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782&#x2013;793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol. 2021;93(5):2555&#x2013;2556. doi: 10.1002/jmv.26624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26624</ArticleId><ArticleId IdType="pubmed">33095459</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Lifelines corona research I. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5):e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396&#x2013;398. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect Dis. 2021;8(6):ofab156. doi: 10.1093/ofid/ofab156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Hermosillo JA, Martinez-Lopez JP, Carrillo-Lampon SA, Ruiz-Ojeda D, Herrera-Ramirez S, Amezcua-Guerra LM, Martinez-Alvarado MDR. Post-acute COVID-19 symptoms, a potential link with myalgic encephalomyelitis/chronic fatigue syndrome: a 6-month survey in a Mexican cohort. Brain Sci. 2021;11(6):760. doi: 10.3390/brainsci11060760.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11060760</ArticleId><ArticleId IdType="pmc">PMC8227652</ArticleId><ArticleId IdType="pubmed">34201087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortini A, Torrigiani A, Sbaragli S, Lo Forte A, Crociani A, Cecchini P, et al. COVID-19: persistence of symptoms and lung alterations after 3&#x2013;6 months from hospital discharge. Infection. 2021;49(5):1007&#x2013;1015. doi: 10.1007/s15010-021-01638-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01638-1</ArticleId><ArticleId IdType="pmc">PMC8179958</ArticleId><ArticleId IdType="pubmed">34091869</ArticleId></ArticleIdList></Reference><Reference><Citation>AlRasheed MM, Al-Aqeel S, Aboheimed GI, AlRasheed NM, Abanmy NO, Alhamid GA, et al. Quality of life, fatigue, and physical symptoms post-COVID-19 condition: a cross-sectional comparative study. Healthcare. 2023;11(11):1660. doi: 10.3390/healthcare11111660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11111660</ArticleId><ArticleId IdType="pmc">PMC10252651</ArticleId><ArticleId IdType="pubmed">37297800</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Palacios-Cena M, Rodriguez-Jimenez J, de-la-Llave-Rincon AI, et al. Fatigue and Dyspnoea as main persistent post-COVID-19 symptoms in previously hospitalized patients: related functional limitations and disability. Respiration. 2022;101(2):132&#x2013;141. doi: 10.1159/000518854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518854</ArticleId><ArticleId IdType="pmc">PMC8678253</ArticleId><ArticleId IdType="pubmed">34569550</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedree H, Sunnquist M, Jason LA. The DePaul symptom questionnaire-2: a validation study. Fatigue. 2019;7(3):166&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367506</ArticleId><ArticleId IdType="pubmed">32685281</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: post-viral syndrome post COVID-19. Med Hypotheses. 2020;144:110055. doi: 10.1016/j.mehy.2020.110055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110055</ArticleId><ArticleId IdType="pmc">PMC7320866</ArticleId><ArticleId IdType="pubmed">32758891</ArticleId></ArticleIdList></Reference><Reference><Citation>Petracek LS, Suskauer SJ, Vickers RF, Patel NR, Violand RL, Swope RL, Rowe PC. Adolescent and young adult ME/CFS after confirmed or probable COVID-19. Front Med. 2021;8:668944. doi: 10.3389/fmed.2021.668944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.668944</ArticleId><ArticleId IdType="pmc">PMC8116546</ArticleId><ArticleId IdType="pubmed">33996867</ArticleId></ArticleIdList></Reference><Reference><Citation>Peppercorn K, Edgar CD, Kleffmann T, Tate WP. A pilot study on the immune cell proteome of long COVID patients shows changes to physiological pathways similar to those in myalgic encephalomyelitis/chronic fatigue syndrome. Sci Rep. 2023;13(1):22068. doi: 10.1038/s41598-023-49402-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-49402-9</ArticleId><ArticleId IdType="pmc">PMC10716514</ArticleId><ArticleId IdType="pubmed">38086949</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health. About ME/CFS? 2022. https://www.nih.gov/mecfs/about-mecfs. Accessed 2 Feb 2024.</Citation></Reference><Reference><Citation>Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med. 1994;121(12):953&#x2013;959. doi: 10.7326/0003-4819-121-12-199412150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chron Fat Syndr. 2003;11(1):7&#x2013;115. doi: 10.1300/J092v11n01_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n01_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327&#x2013;338. doi: 10.1111/j.1365-2796.2011.02428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Population, Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington (DC): National Academies Press (US). Copyright 2015 by the National Academy of Sciences. All rights reserved. 2015.</Citation></Reference><Reference><Citation>Baalbaki N, Blankestijn JM, Abdel-Aziz MI, de Backer J, Bazdar S, Beekers I, et al. Precision medicine for more oxygen (P4O2)-study design and first results of the long COVID-19 extension. J Pers Med. 2023;13(7):1060. doi: 10.3390/jpm13071060.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm13071060</ArticleId><ArticleId IdType="pmc">PMC10381397</ArticleId><ArticleId IdType="pubmed">37511673</ArticleId></ArticleIdList></Reference><Reference><Citation>meetinstrumenten in de zorg. Fatigue Severity Scale (FSS) 2015. https://meetinstrumentenzorg.nl/instrumenten/fatigue-severity-scale/. Accessed 15 Aug 2023</Citation></Reference><Reference><Citation>Twomey R, DeMars J, Franklin K, Culos-Reed SN, Weatherald J, Wrightson JG. Chronic Fatigue and Postexertional Malaise in People Living With Long COVID: An Observational Study. Phys Ther. 2022;102(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383197</ArticleId><ArticleId IdType="pubmed">35079817</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington (DC): National Academies Press (US); 3, Current Case Definitions and Diagnostic Criteria, Terminology, and Symptom Constructs and Clusters. 2015. Available from: https://www.ncbi.nlm.nih.gov/books/NBK284898/.</Citation></Reference><Reference><Citation>Bullinaria JA. Self organizing maps: fundamentals. Introduction to Neural. 2004;15.</Citation></Reference><Reference><Citation>Vaes AW, Van Herck M, Deng Q, Delbressine JM, Jason LA, Spruit MA. Symptom-based clusters in people with ME/CFS: an illustration of clinical variety in a cross-sectional cohort. J Transl Med. 2023;21(1):112. doi: 10.1186/s12967-023-03946-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-03946-6</ArticleId><ArticleId IdType="pmc">PMC9921324</ArticleId><ArticleId IdType="pubmed">36765375</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Comprehensive health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19) Clin Infect Dis. 2021;73(5):e1089&#x2013;e1098. doi: 10.1093/cid/ciaa1750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1750</ArticleId><ArticleId IdType="pmc">PMC7717214</ArticleId><ArticleId IdType="pubmed">33220049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason LA, Islam M, Conroy K, Cotler J, Torres C, Johnson M, Mabie B. COVID-19 symptoms over time: comparing long-haulers to ME/CFS. Fatigue. 2021;9(2):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8411893</ArticleId><ArticleId IdType="pubmed">34484973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>